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Type 1 diabetes mellitus
Collagen glycation
Collagen integrityType 1 diabetes mellitus (T1DM) is a severe disorder characterized by hyperglycemia and hypoinsulinemia. A
higher occurrence of bone fractures has been reported in T1DM, and although bone mineral density is reduced
in this disorder, it is also thought that bone quality may be altered in this chronic pathology. Vibrational micros-
copies such as Fourier transform infraredmicrospectroscopy (FTIRM) represent an interesting approach to study
bone quality as they allow investigation of the collagen andmineral compartment of the extracellular matrix in a
speciﬁc bone location. However, as spectral feature arising from themineralmay overlapwith those of the organ-
ic component, the demineralization of bone sections should be performed for a full investigation of the organic
matrix. The aims of the present study were to (i) develop a new approach, based on the demineralization of
thin bone tissue section to allow a better characterization of the bone organic component by FTIRM, (ii) to vali-
date collagen glycation and collagen integrity in bone tissue and (iii) to better understandwhat alterations of tis-
sue material properties in newly forming bone occur in T1DM.
The streptozotocin-injected mouse (150mg/kg body weight, injected at 8 weeks old) was used as T1DMmodel.
Animals were randomly allocated to control (n = 8) or diabetic (n= 10) groups and were sacriﬁced 4 weeks
post-STZ injection. Bones were collected at necropsy, embedded in polymethylmethacrylate and sectioned
prior to examination by FTIRM. FTIRM collagen parameters were collagen maturity (area ratio between 1660
and 1690 cm−1 subbands), collagen glycation (area ratio between the 1032 cm−1 subband and amide I) and col-
lagen integrity (area ratio between the 1338 cm−1 subband and amide II).
No signiﬁcant differences in the mineral compartment of the bone matrix could be observed between controls
and STZ-injected animals. On the other hand, as compared with controls, STZ-injected animals presented with
signiﬁcant higher value for collagen maturity (17%, p = 0.0048) and collagen glycation (99%, p = 0.0121),
while collagen integrity was signiﬁcantly lower by 170% (p= 0.0121).
This study demonstrated the profound effect of early T1DM on the organic compartment of the bone matrix in
newly forming bone. Further studies in humans are required to ascertainwhether T1DMalso lead to similar effect
on the quality of the bone matrix.
© 2015 Elsevier Inc. All rights reserved.Introduction
Type 1 diabetes mellitus (T1DM) is a severe disorder that persists
through the entire life of affected individuals. T1DM is characterized
by the inability of pancreatic β-cells to secrete insulin and therefore re-
sults in hyperglycemia. Several complications including bone loss and
elevated fracture risk have been reported in T1DM [1,2]. Increased frac-
ture risk could be partially related to diabetic complications such as58, Institut de Biologie en Santé,
, France. Fax: +33 244 688 350.
G. Mabilleau).retinopathy and neuropathy that increase the incidence of fall [3,4].
Another more likely explanation could reside in a direct effect of diabe-
tes on bone tissue. Bone mineral density (BMD), measured by dual en-
ergy X-ray absorptiometry, has been reported to be lower in T1DM
patients as compared to age-matched control subjects [5,6]. However,
elevated fracture risk among T1DM patients still persists even after
adjusting for hip BMD [7]. Furthermore, the low BMD observed in
T1DM does not fully explain the high fracture risk in this population
[8]. Thus, there is a supposition that diabetic bone is more fragile than
non-diabetic bone for a given BMD and that T1DM not only affects
bone microarchitecture, but also bone quality. The role of glucose in
the formation of advanced glycation end products (AGE) is well
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of collagen glycation. As AGE have been associated with a decrease in
the toughness of trabecular and cortical bone [9,10], it is plausible that
a similar mechanism occurs in T1DM.
Rodent models of T1DM are often generated by injection of
streptozotocin (STZ), which is speciﬁc toxic to insulin-producing pan-
creatic beta-cells, and leads to hypoinsulinemia and hyperglycemia
[11]. Several studies using STZ-injected rodent models have been pub-
lished in the last decade and reported inconsistent data on the effect
of T1DMon bone tissuematerial properties, i.e., themineral and organic
component of the bone matrix [12–15]. Previous studies seem suggest
that bone microarchitecture deterioration appears early, while modiﬁ-
cation of intrinsic material, as determined by bone toughness, occurs
later [16]. Furthermore, an inherent problem with the STZ model is
that this compound is often injected around 10 weeks of age, and the
general duration of studies is around 10–12 weeks. As such, most of
the bone tissue has been formed before the onset of diabetes. To date,
the gold standard method to assess the collagen component of the
bone matrix is represented by high-performance liquid chromatogra-
phy (HPLC) that requires prior tissue grinding, reduction and hydrolysis
with acid/alkali. The downside of this approach is that HPLC does not
account for variable turnover rates and tissue age that can modify the
outcome of collagen analysis.
In this regard, vibrational spectroscopy in the mid-infrared (IR) re-
gion can provide molecular structure information about mineralized
and non-mineralized connective tissue [17–19]. In addition, Fourier
transform IR microspectroscopy (FTIRM), in which the spectrometer is
coupled to a light microscope, enables investigators to record spectra
at discrete points within thin tissue section. This methodology has sev-
eral advantages as compared with other approaches, such as X-ray dif-
fraction, nuclear magnetic resonance or HPLC, in (i) allowing the use
of the same sample for other investigations (histomorphometry,
quantitative backscattered electron imaging, nanoindentation, etc.)
and (ii) enabling the investigator to precisely determine tissue material
properties in a speciﬁc location of a bone sample (between double tet-
racycline labels as for example).
Based on IR analyses of single crystals and model compounds, the
origin of vibrations observed in the IR has been tabulated for themineral
and protein component of the bone matrix. Several calculated parame-
ters have been validated for the analyses of bone tissue and are reviewed
in depth elsewhere [20]. As for example, the 900–1200 cm−1 region,
assigned to υ1υ3 phosphate vibrations, is often used to derive informa-
tion regarding the maturity and size of the bone mineral. The 960–
1140 cm−1 region also contains information regarding carbohydrate
moieties [21]. However, the presence of the strong υ1υ3 phosphate at
the samewave number hampers the accurate determination of carbohy-
drate vibrations. As such,we hypothesized that investigation of the same
bone section in amineralized state (native state) followed by demineral-
ization and re-analysis at the same location may be interesting to ascer-
tain whether tissue material properties are affected in T1DM. Such an
approach necessitates the validation of several IR parameters used in
other connective tissue but bone, especially for the determination of col-
lagen glycation and collagen integrity.
Therefore, the aims of the present study were (i) to develop a new
approach, based on the demineralization of thin bone tissue section to
more accurately characterize the organic component of the bonematrix
by FTIRM; (ii) to validate collagen glycation and collagen integrity in
bone tissue; and (iii) to better understandwhat alterations of tissuema-
terial properties occur in T1DM.
Materials and methods
Reagents
All chemicals were purchased from Sigma-Aldrich (Lyon, France)
unless otherwise stated.In vitro glycation of type I collagen
Type I collagen gels were prepared as reported elsewhere [22]. Type
I collagen solution (4 mg/ml in 20 mM acetic acid) was diluted, on ice,
with 0.1% acetic acid and neutralized with 0.4 M NaOH (pH 10.2) in
PBS buffer to form1.5mg/ml gels. A 750 μl aliquot of the neutralized col-
lagen solution was pipetted into wells of a 24-well plate and incubated
at 37 °C overnight to allow for ﬁbril formation. All gels were washed ex-
tensively with distilled water prior to a 60-day period of incubation
with glucose solution. At the end of the incubation period, collagen
gelswere dialyzed againstmilliQwater for aweek, and halfwere depos-
ited onto BaF2 window and allowed to dry to form a uniform ﬁlm prior
to FTIRM measurement. Eight gels per conditions have been analyzed.
In order to assess the glycation level, AGE-speciﬁc ﬂuorescence, in
the remaining half of collagen solutions, was determined using an M2
microplate reader (Molecular Devices, St Gregoire, France) with excita-
tion and emissionwavelengths set at 380 and 440 nm, respectively. The
amount of ﬂuorescence has been calibrated using several quinine sul-
fate concentrations (ranged 0–10 μg/ml). The amount of collagen in
each solution was determined by the BCA method as described else-
where [23]. AGE-speciﬁc ﬂuorescence was then expressed as ﬂuores-
cence intensity, in arbitrary unit/μg collagen.
Animals
A total of 18 youngmale Swiss TOmice (8 weeks old) were randomly
allocated to either the saline-injected control (n= 8) or streptozotocin-
injected diabetic (STZ-150 mg/kg body weight, n= 10) groups. Six days
post-STZ injection, diabeteswas conﬁrmed bymeasurement of blood glu-
cose with an automated glucose oxidase procedure using a Beckman glu-
cose analyzer II (Beckman Instruments, Galway, Ireland). Animals were
injected intraperitoneally with calcein (10 mg/kg) 10 and 2 days before
necropsy. Sacriﬁce was then performed 4 weeks post-STZ injection. All
experiments were carried out according to UK home ofﬁce regulations
(UK Animals Scientiﬁc Procedures act 1986).
Bone tissue processing
At necropsy, femurs were harvested, cleaned of soft tissue
and ﬁxed with 70% ethanol for 24 h at 4 °C and embedded in
polymethylmethacrylate at 4 °C. This ﬁxation/embedding protocol has
previously been successfully employed for FTIRM measurements [24].
Cross-sectional sections (4 μm thickness) of the femur mid-diaphysis
were cut dry on a heavy duty microtome equipped with tungsten car-
bide knives (Leica Polycut S). Four bone sections were analyzed for
each animal. Each section was separated by 15 μm. Sections were ﬁrst
observed with a ﬂuorescence Olympus AX-60 microscope (Olympus
France, Rungis, France) with a 40x magniﬁcation with either bright
ﬁeld or ﬂuorescence light for the visualization of calcein double labeling
(excitation and emissionﬁlters set at 490nmand 520 nm, respectively),
and digital photographswere taken with both illuminations. White and
ﬂuorescent pictures were overimposed using Adobe Photoshop CS5
(Adobe, Paris, France) and were used with demineralized bone section
only to ensure proper locations of the two calcein lines (See Fig. 1). Sec-
tions were then sandwiched between BaF2 windows and ready for
FTIRM data acquisition as detailed below.
FTIRM data acquisition
Spectral acquisitionswere obtained on a Bruker Vertex 70 spectrom-
eter (Bruker optics, Ettlingen, Germany) interfaced with a Bruker
Hyperion 3000 infrared microscope equipped with a standard single
element Mercury Cadmium Telluride (MCT) detector in the range
750–4000 cm−1. The Bruker Hyperion 3000 was also equipped with a
mercury lamp, a 455 nm excitation ﬁlter and a 520 nm emission ﬁlter
(Bruker). The FTIR spectrometer was continuously purged with dry
Table 1
FTIRM parameters.
Parameter Deﬁnition
Mineral phase
Degree of mineralization Area of 900–1200 cm−1 phosphate band/area of amide
I band (1585–1720 cm−1)
Carbonate substitution Area of 850–890 cm−1 band/area of phosphate band
Mineral crystallinity Area of 1030 cm−1 subband/area of 1020 cm−1 subband
Protein phase
Collagen maturity Area of 1660 cm−1 subband/area of 1690 cm−1 subband
Collagen integrity Area of 1338 cm−1 subband/area of amide II band
(1585–1495 cm−1). Reduction in this parameter suggests
collagen denaturation.
Tissue secondary
structure
Relative area of subbands located at 1694 cm−1 (β-turn),
1681 cm−1 (β-sheet), 1669 cm−1 (β-turn), 1656 cm−1
(α-helix), 1647 cm−1 (unordered), 1638 cm−1 (triple helix)
and 1626 cm−1 (β-sheet).
Collagen glycation Area of 1032 cm−1 subbandnarea of amide I band
Parameters in italic can only be assessed after the demineralization of the bone matrix.
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Schwarzchild objective (NA = 0.5), acquisition of spectrum was con-
ducted with the video measurement mode with a pixel size of 1.1 μm.
In this mode, an image is recorded, and markers are manually posi-
tioned at the locations were spectra should be acquired, and then due
to a motorized stage, spectra are recorded at marked locations with an
IR beam size of ~7 μmat 1650 cm−1. Markerswere positionedmanually
in the center of double calcein labels and were spaced by 20 μm. The
number of markers per double calcein regions was variable depending
on calcein labeling length. At least one spectrum was acquired in each
double-labeled surface. At the meantime, marker locations were also
added on the Photoshop-processed images taken above. A minimum
of 40 IR spectra was recorded for each sample at a resolution of
4 cm−1, with an average of 32 scans in transmission mode with the
Opus software (Bruker, release 6.5). Background spectral images were
collected under identical conditions from the same BaF2 windows at
the beginning and end of each experiment to ensure instrument
stability.
FTIRM data processing
The spectral region 850–1800 cm−1 was used for analysis. Each
spectrum, obtained from a pMMA section, was ﬁrst corrected for
polymethylmethacrylate (pMMA) contribution by subtraction of
pMMA background after normalization of the peak at 1730 cm−1. The
40 spectra of each sample were baseline corrected with an elastic cor-
rection method and vector normalized on the range 1495–1720 cm−1.
Spectra were subjected to curve ﬁtting using a commercial available
software package (Grams/AI 8.0, Thermoﬁsher scientiﬁc, Villebon sur
Yvette, France). Brieﬂy, the second derivative spectrumwas used to de-
termine the number and the position of the bands constituting every
spectral interval. Spectral curve ﬁtting quality was assessed by a root
mean square noise (RMSnoise) set at 1%. RMSnoise represent the vari-
ance between the smoothed trace and the original sample spectrum
and is calculated as:
RMSnoise ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
Xn
i¼1
ai−pið Þ2
vuut
where n is the number of data point in the ﬁtted region, a is the true ab-
sorbance value and p is the predicted absorbance value determined by
the Levenberg–Maquardt (LM) algorithm. Initial trace and second de-
rivative were overimposed, and subband was positioned, with a gauss-
ian shape, at minimum intensities observed on the second derivative
spectrum. The LM algorithm was run, and the position and area of
subbands were obtained. Evaluated IR spectral parameters are present-
ed Table 1.
Demineralization protocol
Sections were demineralized by immersion in a solution of 0.5 M
ethylenediaminetetraacetic acid (EDTA) in Tris buffer pH 7.4 for
7 days. The EDTA solution was replenished at day 3. At the end of the
7-day period, sections were rinsed 8 times with Tris solution followed
by 6 washes with milliQ water. Sections were then allowed to dry at
37 °C for 48 h. Sections were then sandwiched between BaF2 windows
and reexamined by FTIRM. As calcein labelswere no longer present after
demineralization, we used the Photoshop-processed image to accurate-
ly determine the location of FTIR markers in the video measurement
mode (Fig. 1). Measurements were then performed as described above.
Enzymatic treatment
Demineralized sections of control animals, already examined by
FTIRM, were incubated in 1 mg/ml type IA-S collagenase or 0.25 mg/mltrypsin (Lonza, Verviers, Belgium) at 37 °C for 10 min. Sections were
then rinsed 6 times in milliQ water and allowed to dry at 37 °C for 48 h.
prior to FTIRM reexamination.
Quantitative backscattered electron imaging (qBEI)
Quantitative backscattered electron imagingwas employed to deter-
mine the bone mineral density distribution (BMDD) of the section be-
fore and after demineralization [25]. Sections were observed with a
scanning electron microscope (EVO LS10, Carl Zeiss Ltd, Nanterre,
France) equipped with a ﬁve quadrants semi-conductor backscattered
electron detector and operated at 20 keV with a probe current of
250 pA and a working distance of 15 mm. The backscattered signal
was calibrated using pure carbon (Z = 6, mean grey level = 25), pure
aluminum (Z = 13, mean grey level =225) and pure silicon (Z = 14,
mean grey level = 253) standards (Micro-analysis Consultants Ltd, St
Ives, UK). Analysis was performed as previously reported [26]. Camean,
representing the mean calcium concentration, was determined.
The composition of the bone section was investigated by energy-
dispersive X-ray analysis (EDX) using an Inca Xmax device (Oxford
Instruments, Oxford, UK). The detection limit of this EDX system was
of 0.01% atomic percentage.
Statistical analysis
Results were expressed as mean ± standard error of the mean
(SEM). Student's t-test with Levene's test of homogeneity was used to
compare the differences between the CTRL and STZ groups using the
Systat statistical software release 13.0 (Systat software Inc., San Jose,
CA). Differences observed in in vitro assayswere assessed using Levene's
test followed by ANOVA and Bonferroni post hoc test. Differences at
p b 0.05 were considered signiﬁcant.
Results
Demineralization efﬁciency
In order to validate our demineralization protocol, we ﬁrst looked at
the mineral presence by qBEI. As shown in Fig. 2A, EDTA treatment led
to a dramatic reduction of signal, suggesting demineralization. Indeed,
EDX analysis conﬁrmed that calcium concentration was drastically re-
duced and phosphorus below the detection limit. Furthermore, Camean,
which represents the mean mineral concentration, decreased to 0
after EDTA treatment, suggesting a mineralization state equivalent to
osteoid tissue and as such the absence of mineral (Fig. 2B). FTIRM
spectra recorded before and after EDTA treatment revealed dramatic
changes (Fig. 2C). First, the large band observed at 900–1200 cm−1,
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treatment, conﬁrming demineralization. Second, the band located at
~870 cm−1, representing υ2 carbonate vibration, is no longer present
in the demineralized bone section. Third, the band located at 1350–
1500 cm−1, representative of υ3 carbonate and CH2 wagging, was dra-
matically modiﬁed by demineralization, to reveal two peaks located re-
spectively at 1451 cm−1 and 1400 cm−1 and corresponding to CH2 and
CH3 wagging of collagen side chain. The band centered at 1338 cm−1,
representing the vibration of amino acid side chain, was better resolved
in demineralized sections.
Assessment of the extent of collagen glycation in collagen gel
Next, to study collagen glycation and identiﬁcation of suitable peak
to measure glycation, we used collagen gels that were incubated in glu-
cose solution. As depicted in Fig. 3A, the main consequence of incuba-
tion with 25 mM glucose was a large band appearing between 960
and 1140 cm−1 on the FTIR spectra and representative of C-O-C, C-OH
and C-C ring vibrations. Curve ﬁtting of this region, based on second de-
rivative analysis, revealed the presence of seven underlying bands locat-
ed at 995 cm−1, 1012 cm−1, 1032 cm−1, 1049 cm−1, 1064 cm−1,
1082 cm−1 and 1101 cm−1 (Fig. 3B). In order to ascertain whether
one of these bands could be used to monitor collagen glycation, we
looked at their respective evolution in the presence of 0, 25 and
50 mM glucose. The subband located at 1032 cm−1 was the biggest
(39.1%) in the region 960–1180 cm−1 at a glucose concentration of
50 mM (Table 2). Furthermore, the 1032 cm−1 subband was the only
subband that showed an increase over the three tested glucose concen-
trations (Table 2). As such, we decided to use this subband for determi-
nation of collagen glycation.
Validation of collagen glycation and collagen integrity parameters
Collagen glycation was determined by calculating the area ratio of
the 1032 cm−1 subband over the Amide I region (Fig. 4A). This ratio
augmented signiﬁcantly in a dose-dependent manner by 10- and 34-
fold with 25 and 50 mM glucose incubations, respectively. Collagen
glycation was also determined by assessing the ﬂuorescence emissionAnalysis of mineral component and
collagen maturity
Bone harvest
Ethanol-based fixation
Embedding in pMMA
Sectionning
Observation of bone section with FTIR microscope
in the fluorescent mode and acquisition
of FTIR spectrum between double calcein labels
EDTA treatment
Localization of ROIs using digital photographs
Acquisition of FTIR spectrum at ROI locations
Analysis of demineralized parameters
Fig. 1. Schematic representationat 440 nm (Fig. 4B). Similarly, the ﬂuorescence intensity (arbitrary
unit/μg collagen) was signiﬁcantly and dose-dependently augmented
by 5- and 12-fold with 25 and 50mMglucose incubations, respectively.
These two methodologies examine collagen glycation and were signiﬁ-
cantly correlated with an R2 value of 0.9992 (p= 0.013). However, no
signiﬁcant modiﬁcation of collagen secondary structure was evidenced
after glycation (Fig. 4C) although a subband located at ~1674 cm−1 was
present in 5 of the 8 collagen gels incubated with 50 mM glucose.
In order to assesswhether collagen integritywas affected by collagen
glycation, we measured this parameter in the presence of 0, 25 and
50 mM glucose. Collagen integrity was unaffected by collagen glycation
(Fig. 4D). We then assessed collagen integrity in demineralized bone
section of control animals before and after enzymatic treatment. The
ratio 1338 cm−1/Amide II was signiﬁcantly reduced after treatment
with collagenase but not with trypsin (p=0.008 and p=0.540 respec-
tively, Fig. 4E). Secondary structure of bone tissue was dramatically al-
tered after collagenase treatment with signiﬁcant augmentations in β-
turn and α-helix and signiﬁcant reductions in unordered and triple
helix (Fig. 4F). On the other hand, trypsin did not signiﬁcantly alter tis-
sue secondary structure.
T1DMdid not alter themineral component of the bonematrix but increased
collagen maturity
Structural parameters were assessed by FTIR in mineralized sections
of control and diabetic mice. No major difference was evidenced in
FTIRM spectra (Fig. 5A). The degree of mineralization, carbonate substi-
tution andmineral crystallinitywere not signiﬁcantly different between
the two groups of animal (Fig. 5B–D). On the other hand, collagen
maturitywas signiﬁcantly increased by 17% (p=0.0048) in diabetic an-
imals as compared to controls (Fig. 5E).
T1DM resulted in dramatic alterations of collagen structural feature
Structural collagen parameters were also investigated in
demineralized bone sections of control and diabetic animals. Again,
no major differences in spectral features were observed between the
two animal groups, except in the region 1000–1050 cm−1, with anObservation of bone section with an
Olympus AX-60 microscope and
localization of double calcein labels
Digital photographs were taken
to make a record of ROIs
with double calcein labels 
of the experimental design.
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Fig. 2. Control of bone section demineralization. (A) Bone sections were imaged by qBEI before and after EDTA treatment. The corresponding EDX analysis showed the absence of phos-
phorus and drastic reduction in calcium after treatment. (B) Camean, representative of the mean mineral content, is dropped to 0 after EDTA treatment. (C) FTIRM spectra of mineralized
(black line) and demineralized (grey line) bone section. ***p b 0.001 vs. before treatment.
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higher in diabetic mice by 99% (p = 0.0121, Fig. 6B). Collagen
integrity was signiﬁcantly lower in diabetic animals by almost 170%
(p = 0.0121, Fig. 6C). Interestingly, we observed signiﬁcant modiﬁ-
cations in tissue secondary structure in diabetic mice with a signiﬁ-
cant higher amount of β-turn (2-fold, p b 0.001) and signiﬁcant
reductions in unordered (3.8-fold, p = 0.018) and triple helix (4.25-
fold, p b 0.001) (Fig. 6D).1700 1500 1300 1100 900 
Bandwidth (cm-1)
(A)
Fig. 3. In vitro glycation of type I collagen gels. (A) FTIRM spectra of control collagen gel (grey line
revealing seven underlying band centered at 995 cm−1, 1012 cm−1, 1032 cm−1, 1049 cm−1, 1Discussion
Worldwide, the number of people who develop T1DM is increasing.
While living with T1DM is manageable with diet, insulin therapy and
exercise, diabetic complications still occur. Among them, bone fracture
represents a severe complication that greatly alters the quality of life.
Despite the need to prevent fracture occurrence, there is a paucity of
mechanistic information on how hypoinsulinemia and hyperglycemiaNo glucose
25mM Glucose
50mM Glucose
1012
995
1032
1049
10641082
1101
(B)
) and after incubationwith 25mMglucose. (B) Curveﬁtting of the 960–1140 cm−1 region,
064 cm−1, 1082 cm−1 and 1101 cm−1.
Table 2
Relative contribution in % of underlying band in the 965–1180 cm−1 region. *p b 0.05 vs.
previous glucose concentration.
Glucose concentration (mM)
Underlying band (cm−1) 0 25 50
995 2.6 ± 0.3 7.6 ± 1.2* 5.0 ± 0.9
1012 13.8 ± 2.0 4.6 ± 1.9* 4.8 ± 1.6
1032 13.3 ± 2.2 28.0 ± 0.8* 39.1 ± 1.0*
1049 5.6 ± 2.0 12.8 ± 4.3* 9.6 ± 3.1
1064 16.9 ± 2.7 17.4 ± 2.0 12.8 ± 2.1
1082 40.4 ± 2.5 8.5 ± 0.7* 12.2 ± 1.2
1101 7.4 ± 2.1 21.2 ± 7.3* 16.5 ± 5.7
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properties. In the present study, an innovative FTIRM analysis of bone
tissue in a mineralized state was used followed by analysis at the
same location upon demineralization. We validated several FTIRM pa-
rameters (collagen glycation, collagen integrity and tissue secondary
structure) that were useful in assessing structural modiﬁcations of the
bone tissue. Furthermore, we demonstrated a signiﬁcant augmentation
of collagen glycation in diabetic bone tissue and also collagen denatur-
ation (reduction in collagen integrity and breakdown of the triple
helix) that could potentially alter bone toughness.
First of all, the demineralization of bone sections led tomodiﬁcations
of spectral feature with biggest modiﬁcations observed in the 1500–
1350 cm−1 and 1200–900 cm−1 regions. In mineralized section, the
1500–1350 cm−1 region was assigned to υ3 carbonate and CH2 wag-
ging. Demineralization led to removal of carbonate moieties as
evidenced by the absence of the ~870 cm−1 υ2 carbonate band. It is le-
gitimate then to assume that themodiﬁcations of the 1500–1350 cm−1
observed in demineralized section also reﬂect the absence of the υ3 car-
bonate vibration and allows a better resolution of underlying peak rep-
resentative of CH2 and CH3 wagging of collagen side chains. The
demineralization of bone sections alsohighlighted changes in the region
1200–900 cm−1with the removal of υ3υ1 phosphate vibrations and the
apparition of underlying peak assigned to carbohydrate moieties.
However, prior to the assignment of any demineralized subbands to col-
lagen properties, several validations were required. In vitro glycation of
type I collagen gel demonstrated that the relative area of the 1032 cm−1
subband of the carbohydrate region was dose-dependently augmented
during glycation of collagen. This correlated with the ﬂuorometric as-
sessment of collagen glycation, a methodology validated for the assess-
ment of AGE in collagen matrix. Taken together, these data suggest that
the 1032 cm−1 subband might be useful in determining collagen
glycation in demineralized bone tissue. However, before further valida-
tion is made to fully ascertain that the 1032/amide I ratio is a marker of
AGE formation, this parameter should be considered as only indicative
of collagen glycation. One might wonder why we did not choose the
entire carbohydrate region (960–1140 cm−1) or any of the other
subbands as markers of collagen glycation. As evidenced in the present
study, the carbohydrate region (960–1140 cm−1) is composed of seven
underlying bands. Some of these subbands (995 cm−1, 1012 cm−1,
1049 cm−1, 1064 cm−1 and 1101 cm−1) were reduced after trypsin
treatment (data not shown), suggesting that these subbands were gen-
erated by non-collagenous proteins. Indeed, this region has been pro-
posed in other connective tissue as a marker of proteoglycan content
[27]. The 1064 cm−1 band was recently reported by Rieppo and co-
workers as a marker of sulfated proteoglycan in cartilage [21]. These
authors showed that enzymatic removal of proteoglycan dramatically
affected this peak. The extracellular bone matrix contains several pro-
teoglycans and, as such, assignment of this peak in bone tissue is more
difﬁcult. The 1082 cm−1 subband can be assigned to the C-O stretching
vibration of carbohydrate but also to the symmetric PO2 stretching vi-
bration [28]. The extracellularmatrix of the bone tissue contains several
phosphorylated proteins (siblings, ﬁbronectin, vitronectin, etc.) thatcould potentially inﬂuence the area of the 1082 cm−1 subband and al-
though phosphorus was not identiﬁed with EDX analysis (detection
limit of 0.01 % atomic percent),we cannot rule out the presence of phos-
phorus trace in the organic matrix that could have modiﬁed the
1082 cm−1 subband. Furthermore, Rieppo and co-workers did not ob-
serve dramatic alteration of the 1032 cm−1 peak upon enzymatic re-
moval of proteoglycan, suggesting that this peak, although located in
the carbohydrate region, might be an indicator of collagen glycation
rather than glycosaminoglycan [21]. In our study, no reduction of the
1032 cm−1 peak was observed upon trypsin digestion, suggesting that
this peak could not be assigned to non-collagenous proteins and/or pro-
teoglycans. Recently, Guilbert et al. reported in an elegant spectroscopic
study that the intensity ratio of the 1032 cm−1 peak over the amide I
peak was increased upon collagen glycation, supporting the use of the
1032 cm−1 band as a marker of collagen glycation [29].
In the current study, we also introduced and validated a parameter
called collagen integrity. In earlier FTIR studies, absorbance of the
1338 cm−1 band was shown to decrease in intensity as collagen dena-
tures [28]. The 1338 cm−1 band is assigned to the CH2 wagging vibra-
tion of collagen amino acid side chains [28]. The 1338 cm−1/amide II
ratio was ﬁrst introduced by West et al., and these authors evidenced
a smaller ratio in osteoarthritic joint as compared to normal [30]. Fur-
ther work to elucidate the molecular origin of this change conﬁrmed
that reduction in the 1338 cm−1 absorbancewas linked to collagen deg-
radation [31]. In the present study, we reported similar ﬁnding in
demineralized bone where the use of collagenase signiﬁcantly reduced
collagen integrity. On the other hand, neither glycation of type I collagen
nor trypsin treatment altered this parameter. This suggests that collagen
integrity in bone tissue is a marker of collagen degradation.
Protein secondary structure was also determined by second deriva-
tive andpeakﬁtting of the amide I region as previously reported [32,33].
For collagen gels, the amide I region reﬂects the secondary structure of
type I collagen. However, the bonematrix is amixed between type I col-
lagen (~90%) and non-collagenous proteins (~10%). As such, informa-
tion obtained from the amide I region of bone tissue reﬂects the
overall secondary structure of this tissue. Nevertheless, collagen is dis-
tinct from other proteins in that this protein comprises three polypep-
tide chains (α-chains), which assemble together to form a triple helix
with a characteristic band at ~1638 cm−1 [34]. In the present study, tis-
sue secondary structurewas dramatically altered by collagenase but not
by trypsin. We failed to evidence any signiﬁcant alteration of collagen
secondary structure upon glycation or trypsin treatment, although a
subband located at ~1674 cm−1 was evidenced in 5 out of 8 collagen
gels incubated with 50 mM glucose. However, collagenase treatment
led to a dramatic change in the bone tissue secondary structure with a
signiﬁcant alteration of the collagen matrix as represented by the de-
crease in the triple helix.
The mineral component of the bone matrix seemed unaffected in
T1DM, despite previous reports of lower mineralization degree in STZ-
induced T1DM [15,35]. However, in these publications, the study period
post-STZ injection as well as the STZ dose were different as compare to
the present study, and it is plausible that mineralization default arises
from this difference. Another possible explanation could reside in the
mouse strain. In the current study, we used Swiss TO mice based on
the fact that the extent of beta-cells destruction in the pancreas, in re-
sponse to STZ injection, is similar to what is observed in humans suffer-
ing of T1DM. However, the spectral signature of the phosphate band
appeared peculiar and the absence of mineral modiﬁcations might
only be valid in this animalmodel. On the other hand, collagenmaturity,
determined onmineralized bone sections, was signiﬁcantly increased in
the diabeticmice. Previously, Saito et al, reported a signiﬁcant reduction
in immature but not in mature collagen crosslinks in theWBN/Kob dia-
betic ratmodel [36]. As collagenmaturity is calculated as the ratio of the
1660 cm−1/1690 cm−1 subbands, respectively, assigned to mature and
immature collagen crosslinks [37], one could expect an increase in col-
lagen maturity in diabetic animals as observed in the present study.
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gen glycation and AGE formation could affect the FTIR-determined col-
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39A. Mieczkowska et al. / Bone 76 (2015) 31–39studies have also reported a higher AGE accumulation in the bone ma-
trix of diabetic animals supporting our results [14,36]. Collagen integrity
was signiﬁcantly lower in diabetic animals and accompanied by
profound changes in tissue secondary structure. As reported above,
collagen integrity was not signiﬁcantly affected by trypsin treatment,
suggesting that the 1338 cm−1 vibration is strictly related to collagen
amino acid side chain. The decrease in collagen integrity and secondary
structure (fall in triple helix) suggests a denaturation of type I collagen
in T1DM. These modiﬁcations cannot be explained by the augmented
collagen glycation but rather by enzymatic degradation of matrix colla-
gen. Interestingly, further reports have beenmade regardinghigherma-
trix metalloproteinase (MMP) activities, mainly MMP-2, MMP-8, MMP-
9, MMP-13 andMMP-14, in connective tissues, other than bone, in type
1 diabetes [38–42]. To the best of our knowledge, MMP activities have
never been assessed in bone tissue of diabetic animals. However, it is
plausible that MMP activities could be increased in T1DM due to the
chronic inﬂammation state, and this could potentially participate to
the reduced collagen integrity by cleaving the triple helix. Furthermore,
all FTRIM measurements have been performed between double calcein
labeling, suggesting that the observed alterations of collagen were not
due to a difference in tissue age and that they appeared fairly quickly
after the onset of diabetes. As such, it is reasonable to assume that the
observed reduction in bone toughness seen in other rodent models of
STZ-induced T1DM could be due to the modiﬁcation of the collagen
component of the bone matrix as evidenced in the present study.
In conclusion, in the present study, we highlighted that investigation
of the bone matrix in a demineralized state brings important structural
feature of the bone tissue. Indeed, several alterations of collagen quality
(collagen glycation, integrity and secondary structure) in the newly
forming bone matrix of diabetic animals have been observed and
could lead to the observed reduction in bone toughness. Further studies
are now required to demonstrate whether these ﬁndings are transpos-
able to bone tissue of individuals affected by T1DM.
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